![]() |
|
|
Vol. 282, Issue 3, 1565-1571, 1997
Host Defence Unit, Imperial College of Science, Technology and Medicine, National Heart and Lung Institute, London, United Kingdom
| |
Abstract |
|---|
|
|
|---|
We have investigated the effect of rolipram, a type IV
phosphodiesterase inhibitor, on Pseudomonas aeruginosa
infection of the respiratory mucosa of an organ culture model and on
the reduction in intracellular cAMP levels seen in human nasal
epithelial cells incubated with P. aeruginosa culture
filtrate. We have compared rolipram with salmeterol, a long-acting
beta-2 agonist, and have also studied the effect of the two
agents together. Infected organ cultures had significantly (P
.05) increased epithelial damage. Rolipram significantly (P
.05) reduced P. aeruginosa-induced epithelial damage and
reduced the total number of bacteria adhering to the respiratory mucosa
(P
.04) in a concentration-dependent manner, although neither
rolipram nor salmeterol affected P. aeruginosa growth in
broth cultures. Rolipram reduced P. aeruginosa-induced mucosal damage more than salmeterol (P
.03). The effect of the two agents was neither additive nor synergistic. Rolipram, salmeterol and both agents together significantly (P
.01) increased
intracellular cAMP levels in epithelial cells treated with P. aeruginosa culture filtrate. Rolipram alone increased cAMP more
than salmeterol or both agents together (P
.01), probably
because of an interaction between the two agents. These results suggest
that agents that elevate intracellular cAMP protect the epithelium
during bacterial infection. Rolipram is more effective than salmeterol
in preventing P. aeruginosa-induced epithelial damage.
| |
Introduction |
|---|
|
|
|---|
P.
aeruginosa is an opportunistic pathogen that frequently colonizes
the respiratory tract of patients with cystic fibrosis, bronchiectasis
and severe chronic bronchitis (Fick, 1989
; Pitt 1986
). It is
particularly associated with progressive and ultimately fatal chronic
respiratory infection in cystic fibrosis. Management of patients with
chronic bronchial infection includes regular postural physiotherapy and
antibiotic therapy for exacerbations (Rayner et al., 1994a
).
However, once P. aeruginosa infection is established, it is
rarely eliminated despite intensive antibiotic therapy (Fick, 1989
).
Chronic P. aeruginosa infection stimulates an exuberant host
inflammatory response (Pier, 1985
), and this may be associated with
deterioration in lung function, increased morbidity and mortality and
impaired quality of life (Fick, 1989
; Pitt, 1986
; Rayner et
al., 1994a
). Patients infected with P. aeruginosa often
require frequent or even continuous antibiotic therapy in order to
suppress the numbers of bacteria in the lung (Hodson et al.,
1981
; Rayner et al., 1994b
), which in turn reduces the level
of inflammation. However, long courses of antibiotics may be poorly
tolerated, and bacterial resistance commonly occurs (Wilson and Tsang,
1994
). It seems unlikely that new antibiotics will improve this
outcome, so preventive and adjunct therapies are important. Oral
corticosteroids (Auerbach et al., 1985
), nonsteroidal anti-inflammatory agents (Llewellyn-Jones et al., 1995
),
mucolytics (Shak et al., 1990
) and immunization (Schaad
et al., 1991
) are currently under investigation.
Numerous studies have demonstrated that bacterial products may
contribute to the pathogenesis of P. aeruginosa in the
airway (Fick, 1989
; Pitt, 1986
; Pier, 1985
). Pyocyanin is a blue
phenazine pigment that is produced by P. aeruginosa and
causes slowing of ciliary beat and disruption of the integrity of the
epithelium in vitro (Wilson et al., 1987
), as
well as slowing of mucociliary transport in guinea pig trachea in
vivo (Munro et al., 1989
). Pyocyanin-induced ciliary
slowing is associated with a decrease in both intracellular cAMP and
ATP, and agents that raise intracellular cAMP inhibit the effect of
pyocyanin on epithelium (Kanthakumar et al., 1993
).
Salmeterol is a long-acting beta-2 agonist (Nials et
al., 1993
; Anderson et al., 1994
; Devalia et
al., 1992
) that reduces pyocyanin-induced declines in both
intracellular cAMP and ATP that are associated with ciliary slowing and
preserves CBF (Kanthakumar et al., 1994
). Salmeterol also
reduces the amount of epithelial damage that occurs in organ cultures
infected with P. aeruginosa, and it reduces ultrastructural
damage in nasal epithelial cells caused by the P. aeruginosa
toxins pyocyanin and elastase (Dowling et al., 1997
). These
data suggest that agents that elevate cAMP may protect respiratory
epithelium from damage caused by bacterial infection.
We have now investigated the effect of rolipram, a type IV phosphodiesterase inhibitor, on P. aeruginosa infection of the respiratory mucosa in vitro and compared the effects of rolipram with those of salmeterol alone, an agent we have studied previously, and with the effects of both agents together. We have also assayed intracellular cAMP levels in human nasal epithelial cells treated with P. aeruginosa culture filtrate in the presence and absence of both agents separately and together.
| |
Materials and Methods |
|---|
|
|
|---|
Bacteriology
P. aeruginosa strain P455 is a clinical isolate that
has been previously studied in our laboratory (Wilson et
al., 1987
; Tsang et al., 1994
; Dowling et
al., 1997
). P455 is a nonmucoid and piliated strain that produces
alkaline protease, elastase, phenazine pigments, lipase, DNAase and
rhamnolipid. P455 was stored at
70°C in a BHI broth (Oxoid,
Basingstoke, UK) and glycerol mixture (Sigma, Poole, Dorset, UK)
(80:20) and then retrieved onto BHI agar. After overnight culture, 2 to
3 colonies were dispersed in 5 ml of BHI broth and incubated overnight
at 37°C with agitation. The culture was diluted with BHI to give an
optical density of 0.365, which previous experiments had shown
corresponded to approximately 1.0 × 108 cfu
ml
1. One milliliter of the culture was then washed twice
through 10 ml of PBS (Oxoid). The bacterial pellet was resuspended in 1 ml of PBS, vortexed and viable counts performed.
Preparation of Salmeterol and Rolipram
Salmeterol hydroxynaphthoate (Glaxo Wellcome, Uxbridge, Middx,
UK) 6.03 mg was dissolved in the minimal amount of glacial acetic acid
and then diluted with PBS to give a concentration of 1 × 10
5 M. This was further diluted with MEM (Gibco, Paisley,
UK) to give a final concentration of 4 × 10
7 M. Rolipram (Glaxo Wellcome) was dissolved in PBS to give a concentration of 9.5 × 10
5 M. This was further diluted with MEM
to give final concentrations of 1 × 10
6 M, 5 × 10
7 M and 1 × 10
7 M.
Organ Cultures
This method has been described previously (Tsang et
al., 1994
; Jackson et al., 1996
; Dowling et
al., 1997
). Briefly, human nasal turbinate tissue was resected
from patients undergoing surgery for nasal obstruction and transported
to the laboratory in MEM containing antibiotics (50 µg/ml
streptomycin, 50 IU/ml penicillin and 50 µg/ml gentamicin).
Dissection was performed in antibiotic medium to yield small squares
approximately 3 mm2 in area and 2 to 3 mm thick. The tissue
was screened for ciliary activity in order to select tissue squares
with at least one fully ciliated edge. The tissue was immersed in
antibiotic medium for at least 4 hr in order to remove commensal
bacteria and then immersed in non-antibiotic-containing medium for at
least 1h in order to remove the antibiotics.
A sterile Petri dish 3.5 cm in diameter (Sterilin, Stone, UK) was placed aseptically within a sterile Petri dish 6.0 cm in diameter. A strip of sterile filter paper (Whatman No. 1, Maidstone, UK) with dimensions approximately 5 mm by 70 mm was soaked in MEM without antibiotics and positioned aseptically across the diameter of the inner Petri dish. The filter paper strip adhered to the base of the inner Petri dish, and each of its moistened ends adhered to the base of the outer Petri dish. A single tissue square was placed, ciliated surface facing upward, on the center of the filter paper strip in the inner Petri dish, and its edges were sealed with agar. Four milliliters of non-antibiotic-containing medium were pipetted into the outer petri dish. The filter paper strip acted as a wick to draw medium from the outer petri dish to the underside of the tissue.
Experimental Design
Protocol 1: The effect of rolipram on P. aeruginosa
infection of organ cultures.
For each experiment
(n = 6), seven organ cultures were prepared: control,
tissue infected with P. aeruginosa alone, tissue incubated
with rolipram alone (5 × 10
7 M and 1 × 10
7 M) and tissue incubated with rolipram (1 × 10
6 M, 5 × 10
7 M and 1 × 10
7 M) and then infected with P. aeruginosa.
Appropriate tissue squares were incubated with 4 ml of rolipram (1 × 10
6 M, 5 × 10
7 M and 1 × 10
7 M) for 30 min before assembly of the organ cultures.
During this time, the other tissue squares were incubated with MEM
alone.
Protocol 2: Comparison of the effect of rolipram and salmeterol
on P. aeruginosa infection of organ cultures.
For each
experiment (n = 6), seven organ cultures were prepared:
control, tissue infected with P. aeruginosa alone, tissue incubated with rolipram alone (1 × 10
6 M), tissue
incubated with rolipram (1 × 10
6 M) and salmeterol
(4 × 10
7 M) together, and tissue incubated with
rolipram (1 × 10
6 M), salmeterol (4 × 10
7 M) or rolipram and salmeterol together (same
concentrations) and then infected with P. aeruginosa. A
salmeterol-alone control was not performed because our previous study
had shown no effect (Dowling et al., 1997
). Appropriate
tissue squares were incubated with 4 ml of rolipram (1 × 10
6 M), 4 ml of salmeterol (4 × 10
7
M), or 4 ml of rolipram and salmeterol together (same concentrations) for 30 min before assembly of the organ culture. During this time, the
other tissue squares were incubated in MEM alone.
Assessment of Tissue by Scanning Electron Microscopy
At the end of each experiment, tissue squares were given a coded number by an independent observer so that the original identity of the samples was unknown during analysis by scanning electron microscopy. Each tissue square was examined using an Hitachi S-4000 scanning electron microscope (Katsuta-shi, Ibaraki-Ken, Japan) by the same observer. The tissue was initially viewed at a magnification of ×50. A transparent acetate sheet with 100 equal squares was placed over the screen of the visual display unit. A predetermined pattern of 40 grid squares was selected for further viewing and analysis at ×3000 magnification. This pattern involved the horizontal axis, the vertical axis and two diagonal axes and yielded a representative survey of the mucosal surface measuring 1.42 × 104 µm2. Care was taken to ensure that there was no overlap of squares in the center of the organ culture. Each square at a magnification of ×3000 was assessed using the same acetate sheet for percentage of the surface area occupied by four mucosal features: mucus, ciliated cells, unciliated cells and damaged epithelium. Extruding cells, cell debris, dead cells and loss of epithelium were scored together in the category of damaged epithelium. Unciliated areas were defined as areas not covered by cilia, with or without microvilli. Summation of the scores made it possible to assess the percentage of each field that was occupied by each mucosal feature.
The bacteria associated with each of the four mucosal features were
counted. An approximation was made when large numbers of bacteria were
present in sheets. In these instances, it was difficult to determine
which mucosal component(s) the bacteria were adhering to, but
observation of the tissue surrounding the bacteria enabled us to make
an estimate. The total number of bacteria adhering to each organ
culture was compared. In order to overcome the difficulty caused by
different proportions of the organ culture surface being occupied by
each mucosal feature, which made comparison between organ cultures
difficult, we divided the total number of bacteria adhering to a
mucosal feature by the proportion of the surface of the organ culture
occupied by that feature (Rayner et al., 1995
). This was
referred to as the density of bacteria adherent to a mucosal feature.
Effect of Rolipram and Salmeterol on P. aeruginosa Growth in BHI Broth
P. aeruginosa (P455) was retrieved onto BHI agar.
After overnight culture, three colonies were dispersed in 5 ml of BHI
broth containing broth alone, rolipram (1 × 10
6 M),
salmeterol (4 × 10
7 M) or rolipram and salmeterol
together (same concentrations) and incubated at 37°C. Viable counts
were performed by standard dilution methods on these cultures hourly
over a period of 8 hr.
Intracellular cAMP Assay
In separate experiments, strips of human nasal ciliated
epithelium were obtained with a cytology brush from both inferior turbinates of healthy volunteers (n = 6) who had been
free of respiratory infection for at least 4 weeks (Wilson et
al., 1987
). This procedure has been approved by the Royal Brompton
Hospital Ethics Committee. The strips were dispersed by gentle
agitation of the brush in a total of 3.5 ml of cell culture medium 199 with Earle's salts and HEPES (Flow Laboratories, Irvine, Scotland, UK). For each experiment, the nasal epithelium in medium 199 was equally divided among five vials so that each contained 700 µl. Three
vials of epithelium were incubated for 30 min at 37°C with rolipram
(1 × 10
6 M), salmeterol (4 × 10
7 M) or rolipram and salmeterol together (same
concentrations).
P. aeruginosa (P455) culture filtrate was prepared by
incubating 2 to 3 colonies in 5 ml of BHI broth for 24 hr. The culture was then centrifuged and filtered through a sterile milipore filter (0.2 µM) to produce a cell-free filtrate. The culture filtrate was
added 1:1 to four of the five vials: the three vials in which the
epithelium had been incubated with pharmacological agents and one of
the two remaining vials that contained epithelium and MEM alone. The
vials were then incubated at 37°C for 2 hr. This time-point was
chosen because of our previous study, which showed that human nasal
epithelial cells exposed to pyocyanin for 2 hr resulted in a decline in
intracellular levels of cAMP and ATP without damaging the cells as
assessed by lactate dehydrogenase release or trypan blue exclusion
(Kanthakumar et al., 1994
). Levels of intracellular cAMP
were then measured with an enzyme immunoassay kit (Amersham
International, Amersham, UK) as previously described (Kanthakumar
et al., 1994
).
Statistics
All values are given as the mean ± S.E.M. unless otherwise
stated. Comparisons of the mean percentage surface area occupied by
each of the four mucosal features and the mean cAMP levels measured in
nasal epithelium were analyzed using the Mann-Whitney U
test. Total bacterial numbers and bacterial densities associated with
each mucosal feature were analyzed using the Wilcoxon signed rank pairs
test. P values
.05 were judged to be significant.
| |
Results |
|---|
|
|
|---|
Bacteria
The mean number [± standard deviation] of P. aeruginosa in 20 µl of PBS used for inoculation of organ
cultures was (9.0 ± 2.6) × 106 cfu for protocol
1 and (3.5 ± 1.3) × 106 cfu for protocol 2. The
inoculating dose was significantly (P
.04) higher in protocol
1. At 8 hr all control organ cultures were sterile, and infected organ
cultures gave a pure growth of P. aeruginosa.
Scanning Electron Microscopy Analysis
Control organ cultures at 8 hr exhibited very little mucosal
damage. Neither rolipram (at all concentrations analyzed) nor rolipram
and salmeterol together had a significant effect on any mucosal
feature. P. aeruginosa infection caused a significant (P
.05) increase in mucosal damage (tables
1 and 2;
fig. 1A). Mucosal damage was observed as
cell debris and dead or extruding cells, and there were areas in which
the epithelium had been stripped away, exposing basal cells and
collagen.
|
|
|
Protocol 1.
Incubation of the tissue for 30 min with rolipram
at the highest concentration significantly (P
.05) reduced the
amount of mucosal damage caused by P. aeruginosa infection.
There were also significantly more ciliated cells present (P
.05) (table 1). The lower concentrations of rolipram (5 × 10
7 M and 1 × 10
7 M) did not protect
the epithelium against P. aeruginosa-induced mucosal damage.
Organ cultures incubated with the lowest concentration of rolipram
(1 × 10
7 M) had significantly (P
.01) more
mucosal damage and fewer ciliated cells after P. aeruginosa
infection than those incubated with rolipram 1 × 10
6 M.
Protocol 2.
Incubation of the tissue for 30 min with rolipram
(1 × 10
6 M), salmeterol (4 × 10
7 M) or both agents together (same concentrations)
before bacterial infection significantly (P
.02) reduced the
amount of mucosal damage and loss of ciliated cells caused by P. aeruginosa infection (table 2; fig. 1B). Tissue incubated with
rolipram before bacterial infection had significantly (P
.03)
less mucosal damage than those incubated with salmeterol, which
suggests that rolipram was more effective at protecting the epithelium
against P. aeruginosa-induced damage than salmeterol (table
2). However, there was no significant difference between rolipram and
salmeterol with respect to loss of ciliated cells (table 2). There was
less mucosal damage with rolipram (1 × 10
6 M) in
the series of experiments in protocol 2 compared with protocol 1. This
may be related to the significantly (P
.04) higher inoculating dose and subsequently the larger bacterial numbers present at the end
of experiments in protocol 1. Incubation of the tissue with both
rolipram and salmeterol before bacterial infection produced neither an
additive nor a synergistic effect with respect to protection. The
difference between rolipram alone and rolipram and salmeterol together
was not statistically significant (P
.29).
P. aeruginosa Adherence to Organ Cultures
The interaction of P. aeruginosa with the organ
cultures was similar to interactions previously reported (Plotkowski
et al., 1991
; Tsang et al., 1994
). Bacteria were
commonly seen adhering to mucus and damaged cells, particularly in the
gaps between separated epithelial cells. P. aeruginosa
sometimes grew in sheets, covering the surface of the tissue in a
biofilm. Sheets of bacteria made counting bacteria difficult and also
obscured the mucosal feature to which they were adherent. In these
instances, an estimate of bacterial numbers was made that was probably
an underestimate, and the mucosal feature to which the bacteria were
adhering was judged at the edge of the sheet. Tissue incubated with
rolipram (1 × 10
6 M) had significantly (P
.04) lower total numbers of bacteria adherent to the mucosal surface
than did tissue infected with P. aeruginosa. However, the
lower concentrations of rolipram (5 × 10
7 M and
1 × 10
7 M) had no effect on the total number of
bacteria compared with P. aeruginosa alone (table
3). Results similar to the effects of
rolipram (10
6 M) were obtained with salmeterol (4 × 10
7 M) and with rolipram (1 × 10
6 M)
and salmeterol (4 × 10
7 M) together (table
4). However, there was no change in the
tropism of bacteria, which still adhered in similar density to damaged cells and mucus rather than to ciliated and unciliated cells (tables 3
and 4).
|
|
The main reason for the decline in the total number of bacteria
adherent to the mucosa was the reduction in the percentage of damaged
epithelium. Thus, although the density of bacteria adherent to damaged
cells remained the same, the total number decreased because of the
reduction in the percentage of damaged epithelium. Neither rolipram
(10
6 M) nor salmeterol (4 × 10
7 M)
nor the two agents together (same concentrations) affected the growth
of P. aeruginosa in BHI broth culture (fig.
2).
|
cAMP Levels in Human Nasal Epithelial Cells
Incubation of nasal epithelium for 2 hr with P. aeruginosa culture filtrate significantly (P
.01) reduced
the level of intracellular cAMP compared with control (fig.
3). Incubation of nasal epithelium for 30 min with rolipram (1 × 10
6 M), salmeterol (4 × 10
7 M) or both agents together (same concentrations)
before the addition of culture filtrate significantly (P
.01)
reduced the decline in intracellular cAMP. Rolipram had a significantly
(P
.01) greater effect on levels of intracellular cAMP than
either salmeterol or both agents together (fig. 3).
|
| |
Discussion |
|---|
|
|
|---|
The effect of P. aeruginosa infection on the
respiratory mucosa in this study was similar to that previously
reported (Tsang et al., 1994
; Dowling et al.,
1997
). P. aeruginosa infection caused epithelial damage that
was associated with preferential loss of ciliated cells in most
experiments. Bacteria adhered most frequently to damaged epithelial
cells and mucus. Tropism of P. aeruginosa for mucus (Ramphal
et al., 1987
) and damaged epithelium (Plotkowski et
al., 1991
; Ramphal and Pyle, 1983
) has been reported by a number of groups.
Rolipram is a PDE inhibitor that is selective for isoenzyme IV.
Clinical studies on the effects of selective PDE inhibitors on
respiratory function in humans are limited, but enoximone, a type III
PDE inhibitor, decreased lung resistance and increased compliance in
chronic obstructive pulmonary disease (Leeman et al., 1987
).
In addition, the administration of zardaverine, a selective PDE III and
IV inhibitor, was found to have a modest but short-lasting
bronchodilator effect in patients with reversible bronchial obstruction
(Brunnee et al., 1992
). Underwood and colleagues (1994)
demonstrated that rolipram (type IV) but not siguazodan (type III)
inhibited antigen-induced contraction of guinea pig isolated trachea
in vitro. In conscious guinea pigs, both zardaverine and the
combination of rolipram and siguazodan were substantially more
effective than rolipram or siguazodan alone at inhibiting aerosol
histamine or leukotriene D4-induced bronchospasm. Investigators have
also focused on the anti-inflammatory action of drugs that inhibit PDE
and so elevate cAMP. For example, the elevation of cAMP in leucocytes
reduced chemotaxis as well as mediator production and release (Bourne
et al., 1974
).
A number of studies have suggested that elevating intracellular cAMP
may have a cytoprotective effect. For example, iloprost, a stable
prostacyclin analog, inhibits neutrophil-mediated lung injury in the
rat (Riva et al., 1990
) and prevents ultrastructural damage
to hamster hepatocytes treated with paracetamol (Nasseri-Sina et
al., 1992
). There is some evidence that cAMP might exert its cytoprotective effect via a calcium-dependent mechanism.
Elevating intracellular cAMP increased the rate of extrusion of
Ca++ across the plasma membrane of human platlets
via the Ca-ATPase pump (Johansson et al., 1992).
Murata and colleagues (1994) demonstrated that superoxide-induced bleb
formation on cultured rat hepatocytes was mediated via
Ca++, and Bickler and Hansen (1994)
showed that membrane
damage as judged by leakage of lactate dehydrogenase occurred
coincidentally with calcium influx and ATP loss in rat cerebrocortical
brain slices.
In our previous study of P. aeruginosa infection of the
respiratory mucosa, salmeterol, a long-acting beta-2 agonist
reduced epithelial damage caused by bacterial infection and also by the P. aeruginosa toxins pyocyanin and elastase. The mechanism
of this protection was not elucidated, but it was inhibited by
propranolol, which indicates that it was beta
receptor-mediated (Dowling et al., 1997
). In the present
study, the effect of salmeterol in reducing the epithelial damage and
loss of ciliated cells caused by P. aeruginosa infection was
confirmed, and we demonstrated that rolipram protected the respiratory
epithelium in a concentration-dependent manner. However, rolipram
(1 × 10
6 M) was significantly (P
.03) more
effective than salmeterol in protecting the epithelium against P. aeruginosa-induced mucosal damage, but the two agents had similar
effects on loss of ciliated cells. P. aeruginosa culture
filtrate, like the bacterial toxin pyocyanin in our previous study
(Kanthakumar et al., 1993
), reduced the cAMP levels in
epithelial cells. Rolipram preserved cAMP levels in the cells more than
salmeterol, which suggests that this is the reason for its greater
protective effect.
Preincubation of the tissue with rolipram (1 × 10
6
M), salmeterol (4 × 10
7 M) or both agents together
(same concentrations) significantly (P
.04) reduced the total
number of bacteria adhering to the respiratory mucosa without altering
bacterial tropism for each mucosal feature (tables 3 and 4). This
effect was probably due to a reduction in the amount of damage caused
by P. aeruginosa to which the bacteria preferentially
adhered (tables 1 and 2). In separate experiments we showed that
rolipram, salmeterol or both agents together did not significantly
affect P. aeruginosa growth in vitro (fig. 2).
Damaged cells may release nutrients that stimulate bacterial growth, so
reducing damage may also limit bacterial numbers in this way.
Suttorp and colleagues (1993) showed that rolipram (1 × 10
6 M) blocked H2O2-induced
endothelial permeability when combined with PGE1, a
receptor-operated adenylate cyclase activator. A possible mechanism of
action involves elevation of intracellular cAMP accompanied by protein
kinase A activation, which might then decrease intracellular free
Ca++. A reduction in the Ca++ signal reduces
myosin light-chain kinase activity, leading to endothelial cell
relaxation and closure of tight junctions (Rasmussen et al.,
1990
). Closure of tight junctions preserves the integrity of the
endothelium and maintains the permeability barrier, thus preventing the
influx of inflammatory cells. This mechanism may also operate for
epithelial tight junctions and thus maintain epithelial integrity,
which in turn may protect against epithelial damage. Rolipram has other
anti-inflammatory actions. It significantly increased cAMP levels in
BAL leukocytes, and it decreased BAL IL-8, TNF, eosinophils and
neutrophils in response to allergen challenge in monkeys (Turner
et al., 1994
), as well as lipopolysaccharide-induced TNF
synthesis by peripheral blood monocytes (Seldon et al.,
1994
). Because lipopolysaccharide induces cytokine production by
epithelial cells (Khair et al., 1994
), inhibition of their
production by rolipram may be involved in the cytoprotective effect.
Tomlinson and colleagues (1995) used human airway smooth muscle cells
to show that a combination of a nonspecific PDE inhibitor, IBMX, with
the beta-2 agonist salbutamol produced an additive inhibitory effect on thrombin-induced mitogenesis. In the present study, we found that the combination of rolipram and salmeterol did not
produce an additive or synergistic effect with respect to intracellular
cAMP levels in epithelial cells exposed to P. aeruginosa
culture filtrate, nor did it confer protection against P. aeruginosa-induced epithelial damage. In fact, surprisingly, rolipram and salmeterol together were significantly (P
.01) less effective than rolipram alone with respect to intracellular cAMP
levels, and they seemed to be less effective than rolipram alone with
respect to protection against P. aeruginosa-induced epithelial damage, although this difference was not significant. Torphy
and colleagues (1992) showed that combined treatment of the human
monocyte cell line U937 with the beta-2 agonist salbutamol (1 µM) and rolipram (30 µM) for 4 hr resulted in a 2- to 3-fold increase in PDE type IV activity. In the same system, rolipram alone
was without effect and salbutamol alone had half the effect of both
agents together with respect to PDE IV activity. Salmeterol is only a
partial agonist with respect to cAMP, which could explain why rolipram
increased cAMP levels more effectively than salmeterol in our study,
and the results of Torphy and colleagues (1992) might explain why both
agents together did not produce an additive or synergistic effect,
because the up-regulated PDE activity might reduce intracellular cAMP
levels.
In summary, our results show that two agents that elevate intracellular cAMP by different mechanisms protect the epithelium against damage caused by bacterial infection. Rolipram is more effective in achieving this than salmeterol. This may be because salmeterol is a partial agonist with respect to increasing intracellular cAMP levels. The two agents may interact together in some way such that their effect is not additive.
| |
Acknowledgments |
|---|
We would like to thank Mr. Andrew Rutman for his assistance in developing and printing the published micrographs.
| |
Footnotes |
|---|
Accepted for publication May 6, 1997.
Received for publication October 9, 1996.
1 Present address: Glaxo Wellcome Research and Development, Stockley Park West, Uxbridge, Middlesex, UB11 1BU, UK.
Send reprint requests to: Dr. R. Wilson, M.D., FRCP, Host Defence Unit, National Heart and Lung Institute, Emmanuel Kaye Building, Manresa Road, London SW3 6LR, UK.
| |
Abbreviations |
|---|
PDE, phosphodieterase; BHI, brain heart infusion; PBS, phosphate-buffered saline; MEM, minimal essential medium; BAL, bronchoalveolar lavage; IL-8, interleukin-8; TNF, tumor necrosis factor; IBMX, 3-isobutyl-1-methylxanthine.
| |
References |
|---|
|
|
|---|
and expression of ICAM-1 in cultured human bronchial epithelial cells.
Eur. Respir. J.
7: 2109-2116, 1994[Abstract].
2-adrenoceptor agonist, salmeterol.
Br. J. Pharmacol.
108: 507-515, 1993[Medline].
-adrenoceptor agonists suppress lipopolysaccharide-induced tumour necrosis factor
generation by human peripheral blood monocytes.
Br. J. Pharmacol.
112: 215P, 1994.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||